Considering Patient Sex in Prescribing CGRP Receptor Antagonists for Short-Term Treatment of Migraine
Authors:
- 1 September 2023
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 80 (9) , 885-886
Abstract
This Viewpoint describes the relevance of sex-specific differences in the treatment of migraine, including in evidence from trials of CGRP therapeutics, and the clinical implications for decision-making in practice and trial design.Keywords
This publication has 4 references indexed in Scilit:
- Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptorsScience Translational Medicine, 2022
- A Female-Specific Role for Calcitonin Gene-Related Peptide (CGRP) in Rodent Pain ModelsThe Journal of Neuroscience, 2022
- Dural Calcitonin Gene-Related Peptide Produces Female-Specific Responses in Rodent Migraine ModelsThe Journal of Neuroscience, 2019
- Migraine induction with calcitonin gene-related peptide in patients from erenumab trialsThe Journal of Headache and Pain, 2018